Capricor Therapeutics, Inc. (CAPR)

Capricor Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	27.1	25.18	2.55	0.24	0.31	1.01
Revenue Growth (YoY)	389.30%	886.81%	941.85%	-21.06%	-69.13%	-39.87%
Gross Profit	27.1	25.18	2.55	0.24	0.31	1.01
Selling, General & Admin	13.37	12.81	10.43	7.61	5.54	3.6
Research & Development	39.89	36.45	21.82	13.57	8.46	5.14
Operating Expenses	53.26	49.26	32.25	21.18	14	8.74
Operating Income	-26.16	-24.08	-29.7	-20.94	-13.69	-7.73
Other Expense / Income	-1.85	-1.79	-0.68	-0.92	-0.03	-0.09
Pretax Income	-24.31	-22.29	-29.02	-20.02	-13.66	-7.64
Net Income	-24.31	-22.29	-29.02	-20.02	-13.66	-7.64
Shares Outstanding (Basic)	31	27	25	23	16	4
Shares Outstanding (Diluted)	31	27	25	23	16	4
Shares Change	24.19%	9.06%	6.34%	48.28%	319.55%	26.19%
EPS (Basic)	-0.83	-0.83	-1.18	-0.87	-0.88	-2.06
EPS (Diluted)	-0.83	-0.83	-1.18	-0.87	-0.88	-2.06
Free Cash Flow	-33.33	-27.64	1.56	-18.01	-10.6	-6.82
Free Cash Flow Per Share	-1.06	-1.03	0.06	-0.78	-0.68	-1.84
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-96.53%	-95.63%	-1163.93%	-8549.86%	-4412.56%	-769.52%
Profit Margin	-89.72%	-88.52%	-1137.37%	-8175.86%	-4401.94%	-760.36%
Free Cash Flow Margin	-123.01%	-109.79%	61.02%	-7352.29%	-3417.38%	-678.74%
EBITDA	-23.14	-21.22	-28.49	-19.78	-13.51	-7.47
EBITDA Margin	-85.40%	-84.27%	-1116.47%	-8075.53%	-4355.56%	-743.25%
Depreciation & Amortization	1.17	1.07	0.53	0.25	0.14	0.17
EBIT	-24.31	-22.29	-29.02	-20.02	-13.66	-7.64
EBIT Margin	-89.72%	-88.52%	-1137.37%	-8175.86%	-4401.94%	-760.36%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).